Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
주식 순위 #25865
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
주가
$1.21
마지막 동기화: 2026-08-20
시가총액
$45.55M
변동 (1일)
-2.43%
변동 (1년)
-34.60%
국가
US
거래 Metagenomi, Inc. Common Stock (MGX)

카테고리

Metagenomi, Inc. Common Stock (MGX)의 배당 이력
Metagenomi, Inc. Common Stock (주식 심볼: MGX)은 총 0회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): 0.00
배당 수익률 (TTM): 0
Metagenomi, Inc. Common Stock (MGX)의 2026부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
모든 배당 지급 목록
연도 배당금 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
0.00%
US